The DOI matches its Crossref record; 59 of the 63 references it cites were found in a registry or an index.
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Abstract
Background Antidepressant drugs can promote remission from acute depressive episodes. Our aim was to establish how long such treatments should be continued to prevent relapse. Method We did a systematic overview of evidence from randomised trials of continuing treatment with antidepressants in patients with depressive disorders who have responded to acute treatment. Medline, Embase, Cinahl, PsycLIT, Psyndex, and Lilacs were searched. Findings Data were pooled from 31 randomised trials (4410 participants). Continuing treatment with antidepressants reduced the odds of relapse by 70% (95% CI 62-78; 2p Interpretation Antidepressants reduce the risk of relapse in depressive disorder, and continued treatment with antidepressants would benefit many patients with recurrent depressive disorder. The treatment benefit for an individual patient will depend on their absolute risk of relapse with greater absolute benefits in those at higher risk. Further trials are needed to establish the optimum length of therapy and should include patients who were not well represented in these trials, including those at low risk of relapse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, evidence showed no association between relapse rates and duration of treatment (Geddes 2003)”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Geddes 2003
In the citing paper
“Evidence suggests that continuation of antidepressant treatment is effective, as it reduces risk of relapse and recurrence by 50% to 70% (Geddes 2003;Glue 2010;Kaymaz 2008)”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Geddes 2003
In the citing paper
“Continuation treatment should be continued for at least two years a er remission for those at high risk of relapse (APA 2010;CANMAT 2016;Declercq 2017;NHG 2012;NICE 2009;WHO 2017), which is defined as having two or more episodes, residual symptoms, or severe previous episodes (Geddes 2003).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Geddes 2003
In the citing paper
“These time points were based on the findings of the Geddes 2003 review, in spite of the fact that there was no association between relapse rate and duration of treatment in this review.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Geddes 2003
In the citing paper
“However, these recommendations are based on consensus and were introduced into guidelines without evidence.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Geddes 2003
24 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Self-citationDistributed Disturbances in Brain Structure and Function in Schizophrenia
(2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 969
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Hirschfeld, R. M. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280071036 · Cited by 895
Research works printed but not linked: 4
- 2000, Practice guideline for the treatment of patients with major depressive disorder (revision), Am J Psychiatry, 157, 1
- Eric, 1991, A prospective double-blind comparative multi-centre study of paroxetine in preventing recurrent major depressive episodes, Biol Psychiatry, 29, 11
- Lendresse, 1985, Traitement prolongé par nomifensine 75mg dans les états dépressifs neurotiques et reactionnels, Psychiatrie Francaise, 16, 156
- Rouillon, 1989, Rechutes de dépression unipolaire et efficacité de la maprotiline, Encephale, 15, 527
Cited by
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
“The evidence supporting their use in the long-term prophylaxis of unipolar depression is strong (I, (Geddes et al., 2003)).”
Self-citationAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Mindfulness-based cognitive therapy to prevent relapse in recurrent depression.
Kuyken, W., Byford, S., Taylor, R. S., Watkins, E., Holden, E., White, K., Barrett, B., Byng, R., Evans, A., Mullan, E., et al. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0013786 · Cited by 770
“First, given that m-ADM over at least 2 years is recommended to prevent relapse/ recurrence (Geddes et al., 2003; NICE, 2004) and many patients express a preference for an alternative approach, it is important to establish whether MBCT enables patients to taper/discontinue ADM.”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“A meta-analysis of discontinuation RCTs in patients with mainly recurrent depression found that 60% of patients on placebo relapsed in the year after randomisation and 29% relapsed in months 12–36 (Geddes et al., 2003).”
BackgroundMethodResultInfluentialSelf-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Clinical consensus In placebo-controlled continuation therapy trials, mostly with TCA, relapse rates ranged from 31 to 80% for those patients who received placebo, compared with only 0 to 31% of those who received active medication (Prien and Kupfer 1986; Prien 1990; Geddes et al. 2003).”
Background
Metadata
- Authors
- Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M.
- Affiliations
- Warneford Hospital (GB)
- University of Oxford (GB)
- UPMC Health System (US)
- Corresponding author
- Geddes, John R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2003-02
- Volume
- 361
- Issue
- 9358
- Pages
- 653-661
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133308299
- Cited by
- 945
- References
- 63
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 27 · 2023: 23 · 2022: 23 · 2021: 39 · 2020: 61 · 2019: 33 · 2018: 31 · 2017: 39 · 2016: 65 · 2015: 39 · 2014: 46 · 2013: 41 · 2012: 52
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- antidepressants, relapse prevention, depressive disorders, recurrent depression, continuation treatment, treatment discontinuation, remission, medication adherence, placebo response, treatment duration
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. https://app.cochat.ai/papers/10.1016/s0140-6736(03)12599-8
- The paper
- Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. The Lancet. https://doi.org/10.1016/s0140-6736(03)12599-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.